- Design
- Systematic review and meta-analysis of observational cohorts
- Population
- 669 SGLT2 inhibitor-exposed pregnancies in women with type 2 diabetes, three cohorts
- Primary outcome
- Major congenital malformations versus active comparators
- Effect
- RR 0.94 (95% CI 0.68–1.29) versus insulin; cardiac malformations RR 0.97 (0.64–1.48)
Three observational cohorts with 669 pregnancies exposed to an SGLT2 inhibitor around conception or in early pregnancy were pooled against active antidiabetic comparators in women with type 2 diabetes. Against insulin, there was no association with major congenital malformations or with cardiac malformations. Adding a sulfonylurea comparator gave a similar answer.
The confidence intervals are wide enough that a clinically important rise in risk cannot be excluded, and the authors grade certainty as low to very low because of confounding, analysis restricted to live births, and few exposed events. One Korean cohort reported more congenital heart defects with exposure in gestational weeks 4–10, a timing-specific signal that needs replication.
In practice, this is reassurance for the woman who discovers she is pregnant on dapagliflozin or empagliflozin, not permission to continue the drug through pregnancy. Labels still advise against use in pregnancy. The real lesson is upstream: SGLT2 inhibitors are now prescribed for heart and kidney protection to many women of reproductive age, so contraception and pregnancy plans belong in the prescribing conversation.
- Ask about pregnancy plans and contraception when starting an SGLT2 inhibitor in a woman of reproductive age.
- Plan a switch to insulin before conception in women with type 2 diabetes who intend pregnancy.
- After inadvertent first-trimester exposure, stop the drug and counsel that pooled data show no clear rise in major malformations.
- Consider offering a detailed fetal anomaly scan, including cardiac views, where exposure fell in weeks 4–10.
Why it matters
SGLT2 inhibitors have moved into cardiorenal care, so more women of reproductive age are taking them without a pregnancy plan.
Don't overread it
Absence of a pooled signal in three small cohorts is not evidence of safety in pregnancy.
The statistics, in plain English
A risk ratio of 0.94 means malformations were about as common with SGLT2 inhibitors as with insulin. The 95% confidence interval of 0.68 to 1.29 crosses 1.0, so the data fit anything from a modest reduction to a 29% increase. With only three cohorts, a single study's cardiac signal (RR 2.79, CI 1.16–7.06) cannot be dismissed or confirmed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free